Microsensor Measures Intraocular Pressure in Glaucoma
By HospiMedica International staff writers Posted on 18 Aug 2014 |
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
An implantable microsensor for wireless intraocular pressure (IOP) measurement allows close monitoring of patients’ disease status and glaucoma therapy success.
The Pro-IOP eye pressure measurement system consists of an implantable microsensor, an external hand held device that telemetrically transfers energy to the microsensor, and a cellular GSM module, which connects with the hand held device to transfer measurement data to a database that can be accessed by clinicians to review the disease status of the patient. Optionally, the patient can also have limited access to the data via an App, in order to review data history or communicate with the ophthalmologist.
The Pro-IOP delivers direct and real IOP, as expressed in mm Hg, which facilitates measurement without disrupting the patient’s lifestyle and without compromising the patient’s behavior. At the same time, the system discloses to clinicians real time, crucial information regarding patient specific pressure fluctuation and variability, shows if the chosen therapeutic measures work, and reports patient therapy adherence. The system is designed for easy patient use and can also be integrated into telemedicine systems for remote patient management.
The Pro-IOP eye pressure measurement system is a product of Implandata Ophthalmic Products (Hannover, Germany). The company has recently reported the successful implantation of the first patient within the ARGOS-02 clinical study, held at Augenklinik Bellevue (Kiel, Germany). In the ARGOS-02 clinical study, six eye centers in Germany are currently recruiting primary open angle glaucoma patients undergoing cataract extraction.
“So far the first results of this innovative product are very compelling,” said Prof. Detlef Uthoff, MD, medical director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient.”
Related Links:
Implandata Ophthalmic Products
Augenklinik Bellevue
The Pro-IOP eye pressure measurement system consists of an implantable microsensor, an external hand held device that telemetrically transfers energy to the microsensor, and a cellular GSM module, which connects with the hand held device to transfer measurement data to a database that can be accessed by clinicians to review the disease status of the patient. Optionally, the patient can also have limited access to the data via an App, in order to review data history or communicate with the ophthalmologist.
The Pro-IOP delivers direct and real IOP, as expressed in mm Hg, which facilitates measurement without disrupting the patient’s lifestyle and without compromising the patient’s behavior. At the same time, the system discloses to clinicians real time, crucial information regarding patient specific pressure fluctuation and variability, shows if the chosen therapeutic measures work, and reports patient therapy adherence. The system is designed for easy patient use and can also be integrated into telemedicine systems for remote patient management.
The Pro-IOP eye pressure measurement system is a product of Implandata Ophthalmic Products (Hannover, Germany). The company has recently reported the successful implantation of the first patient within the ARGOS-02 clinical study, held at Augenklinik Bellevue (Kiel, Germany). In the ARGOS-02 clinical study, six eye centers in Germany are currently recruiting primary open angle glaucoma patients undergoing cataract extraction.
“So far the first results of this innovative product are very compelling,” said Prof. Detlef Uthoff, MD, medical director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient.”
Related Links:
Implandata Ophthalmic Products
Augenklinik Bellevue
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Latest Critical Care News
- Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients
- Peptide-Based Hydrogels Repair Damaged Organs and Tissues On-The-Spot
- One-Hour Endoscopic Procedure Could Eliminate Need for Insulin for Type 2 Diabetes
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure